|Bid||93.35 x 800|
|Ask||93.97 x 1400|
|Day's range||92.47 - 94.08|
|52-week range||70.89 - 94.56|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||33.01|
|Earnings date||27 Apr 2022 - 02 May 2022|
|Forward dividend & yield||2.76 (3.05%)|
|Ex-dividend date||14 Mar 2022|
|1y target est||95.73|
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Rates could spike sooner rather than later. Prepare your portfolio.
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.